The standard treatment for acute deep venous thrombosis (DVT) has been a short course of intravenous unfractioned heparin (UFH) followed by oral anticoagulants (OAs) for at least 3 months. 1,2 Although this treatment has been effective in decreasing mortality and thromboembolic events, there is a significant risk of hemorrhage, and the patient receiving this therapy requires hospitalization and continuous laboratory monitoring during initial and long-term treatment. Moreover, it does not prevent the development of long-term venous insufficiency and post-thrombotic syndrome (PTS). 2 Recent studies have shown that initial treatment with low molecular weight heparins (LMWHs) is equally or more effective and safer than UFH, 3, 4 and LMWHs are now used in several countries as the initial treatment of choice for most patients with DVT. [5] [6] [7] The pharmacologic lysis of a thrombus located in the deep venous system is an attractive therapeutic option, because removal of this mass could prevent postthrombotic symptoms if lysis occurs before valves are destroyed. 8, 9 Fibrinolytic therapy was introduced because of this, although the risk of acute major bleeding outweighed the potential benefit of a diminished risk for PTS. Therefore, the routine use of fibrinolytic therapy is currently not defendable. 3 The direct or indirect thrombolytic effect of LMWH has been observed in several experimental studies [10] [11] [12] [13] and is likely to occur in humans, [14] [15] [16] [17] which would lead to a reduction of thrombus size, thereby preventing venous dysfunction with a low risk of bleeding. 18 Long-term administration of LMWH in the secondary prophylaxis of thromboembolic events has been used in Purpose: The purpose of this study was to evaluate whether low molecular weight heparin (LMWH) could be equal or more effective than conventional oral anticoagulants (OAs) in the long-term treatment of deep venous thrombosis (DVT). Methods: One hundred fifty-eight patients with symptomatic DVT of the lower limbs confirmed by means of duplex ultrasound scan were randomized to receive 3 to 6 months' treatment with nadroparine calcium or acenocoumarol. Quantitative and qualitative duplex scan scoring systems were used to study the evolution of thrombosis in both groups at 1, 3, 6, and 12 months. Results: During the 12-month surveillance period, two (2.5%) of the 81 patients who received LMWH and seven (9%) of the 77 patients who received OAs had recurrence of venous thrombosis (not significant). In the LMWH group no cases of major bleeding were found, and four cases (5.2%) occurred in the OA group (not significant). The mortality rate was nine (11.1%) in the LMWH group and 7.8% in the OA group (not significant). The quantitative mean duplex scan score decreased in both groups during the follow-up and had statistical significance after long-term LMWH treatment on iliofemoral DVT (1, 3, 6, and 12 months), femoropopliteal DVT (1-3 months), and infrapopliteal DVT (first month). Duplex scan evaluation showed that the rate of venous recanalization significantly increased in the common femoral vein at 6 and at 12 months and during each point of follow-up in the superficial and popliteal veins in the LMWH group. Reflux was significantly less frequent in communicating veins after LMWH treatment (17.9% vs 32.2% in the OA group). The reflux rates in the superficial (22.4% in the LMWH group, 30.6% in OA group) and deep (13.4% vs 17.7%) venous system showed no significant differences between groups. Conclusions: The unmonitored subcutaneous administration of nadroparine in fixed daily doses was more effective than oral acenocoumarol with laboratory control adjustment in achieving recanalization of leg thrombi. With nadroparine, there was less late valvular communicating vein insufficiency, and it was at least as efficacious and safe as oral anticoagulants after long-term administration. These results suggest that LMWHs may therefore represent a real therapeutic advance in the long-term management of DVT. (J Vasc Surg 2001;33:77-90.)
patients who have a high risk of bleeding, in those who present with complications from OAs, or in those whose OA therapy could not be monitored easily. [18] [19] [20] [21] [22] [23] LMWH has a less-activating effect on osteoclasts than the UFH, which thereby reduces osteoporosis as a result of longterm administration. 20, 24, 25 This effectiveness of LMWH therapy raises the important practical question of whether LMWH can be used to treat all patients with DVT over the long term.
The aim of the current study was to evaluate if LMWH administration can be used as an alternative to long-term OAs in patients with DVT, to minimize the prevalence and severity of early-medium complications (recurrent thromboembolic events, death, and major bleeding) and later sequelae (PTS), and to further facilitate the outpatient management of DVT.
MATERIALS AND METHODS
Patients. Consecutive symptomatic patients who were referred to the vascular laboratory in our hospital in whom lower limb DVT was objectively documented with duplex scan examination were considered for entry into the study. Patients were excluded if they were younger than 18 years, were pregnant, had previous episodes of DVT in the same limb, had a past complication due to heparin or acenocoumarol, received full doses of anticoagulants at the time of referral, had surgery within the last 5 days, or refused to give their informed consent. All exclusions were documented.
The study protocol was approved by the Hospital Ethics Committee. All patients gave their written consent for participation in the study according to the Helsinki declaration.
Regimens of treatment. Prefilled syringes were used containing 10.25 AXa IU/mL of nadroparine calcium (Fraxiparina; Sanofi Winthrop, Paris, France). As soon as the patients were included in the study, a subcutaneous dose of nadroparine adjusted to body weight (0.1 mL/10 kg) was administered. Because of methodologic requirements of the study, all patients were hospitalized during the initial course of treatment, and a set dose of nadroparine was subcutaneously administered every 12 hours. Whenever possible, patients were allowed to walk on the third day; they wore elastic graduated compression stockings or bandages. After informed consent for the study was obtained, patients were allocated at random on the third day to receive an LMWH or an OA. In view of the nature of the treatments, it was not possible to use a double-blind design for the study.
In those patients allocated to the LMWH group, fixed subcutaneous doses of nadroparine twice a day were continued at home and were usually administered by the patients themselves, by relatives, or occasionally by nurses from the local primary care centers. In patients randomized to OA, acenocoumarol (Sintrom; Novartis, Basel, Switzerland) was administered once a day beginning on the third day with an initial dose of 4 mg. Further doses were adjusted to obtain an international normalized ratio (INR) between 2 and 3. LMWH was given to overlap with OA and was discontinued when the INR was 2.0 or more in two consecutive measurements 24 hours apart after at least 5 days of initial treatment. 26 After discharge, those patients attended the hematologic unit for routine monitoring of OA therapy to maintain the INR between 2 and 3. The intensity of oral anticoagulation was expressed as the percentage of laboratory determinations at the hematologic unit in which a patient had an INR less than 2, from 2 to 3, or more than 3 with this period calculated with lineal interpolation. 26 Both treatments continued for 3 months and were prolonged for 6 months when the DVT affected the iliac or femoral veins and if the patient had persistent risk factors for thrombosis or an idiopathic DVT. 27 After the third month, nadroparine was administered once a day at fixed doses of 0.1 mL/10 kg, whereas the dosage of acenocoumarol was set to maintain the INR between 2 and 3.
Duplex scan evaluation. All DVTs were confirmed by combining B-mode color imaging and Doppler scan measurements. Venous duplex scan examinations were performed with a Philips P-700 scanner (Philips, Einthoven, The Netherlands) and a 5-or 7.5-MHz probe, depending on the depth of the veins. We examined deep veins: common and external iliac veins, the common femoral vein (CFV), the superficial femoral vein (SFV) along the thigh, the popliteal vein (PV), and the infrapopliteal vein. Also, the superficial long and lesser saphenous veins were examined. The standard findings of partial or complete venous incompressibility and absent or diminished Doppler flow signals were analyzed. 28 For the evaluation of DVT at diagnosis and at 1, 3, 6, and 12 months of follow-up, an objective and reproducible quantitative duplex scan score was obtained with the addition of degrees of thrombi present in the CFV, the SFV, and the PV with five grades at each segment: 4 points for complete occlusion (100%), 3 for severe occlusion (61%-99%), 2 for intermediate occlusion (31%-60%), 1 for slight thrombosis (1%-30%) and 0 for patency (0%). 29 Maximum value for this score was 12 points (4 × 3). The iliac vein segment was routinely explored; however, because of the limitations of duplex scan examinations for establishing the exact degree of thrombosis into the venous lumen at this level, 30, 31 it was not used for calculations of overall scores.
Because measurements of lumen occupation of the infrapopliteal veins were imprecise, thrombosis at this level was scored according to location alone; a 1 / 2 point value was applied for each thrombosed vein: double tibial (anterior tibial, posterior tibial, peroneal) and muscular veins (soleal, gastrocnemius). The maximum possible value for this score was 4 points ( 1 / 2 × 8).
The evolution of thrombosis was qualitatively scored during follow-up with duplex scan examination of the residual thrombus in the CFV, the SFV, and the PV. Thrombus scores for both groups at 1, 3, 6, and 12 months were compared with baseline scores, which reflected recanalization (complete lysis or improvement > 90%), substantial regression (improvement of 60%-90%), moderate regression (30%-60%), slight regression (< 30%), unchanged, and propagation. 32 A repeat duplex scan was performed 24 to 48 hours after standard examination when proximal or distal thrombus extension (thrombosis in a previously unaffected venous segment) or worsening (increased degree of thrombosis in a previously affected venous segment) was found.
Additionally, at 6 and 12 months, the duplex scan followup examination included checks on the presence of venous flow and reflux in deep veins, superficial veins, and communicating veins. Reflux was defined as reversed flow with a velocity of more than 10 cm/s 33 or valve closure lasting more than 2 seconds 34 during proximal or distal compression, which was confirmed with cuff compression. The duplex scan examinations (diagnosis and follow-up) were interpreted independently, without knowledge of allocation to groups to prevent bias.
Surveillance and follow-up. All patients were carefully examined daily during initial LMWH therapy, with special emphasis on signs of bleeding or recurrence of DTV. The following parameters were measured at admission: red blood cell (RBC) count, hematocrit, hemoglobin level, white blood cell (WBC) count, platelet count, activated partial thromboplastin time, prothrombin time, and thrombin time. Measurements were repeated on days 3 and 7.
During surveillance all patients were seen routinely in our vascular clinic 1, 3, 6, and 12 months after diagnosis and were instructed to report at once if symptoms or signs suggestive of recurrent DVT, pulmonary thromboembolism, bleeding, or other complications developed. At these visits, patients underwent clinical examination; their limbs were evaluated for tenderness, edema, varicose veins, hyperpigmentation, or ulceration. The presence of local complications was documented, and their diameters were measured. The circumferences of both limbs were recorded, and duplex scan examination was performed. RBC count, WBC count, platelet count, activated partial thromboplastin time, prothrombin time, INR, and thrombin time were determined at 1, 3, and 6 months. Patient compliance was monitored in both groups.
Information was obtained on every subsequent hospital admission, and the cause of death was documented for patients who died. The efficacy of treatment was assessed in terms of the absence or decrease of complications of DVT or treatment and improvement in clot size.
Complications. The primary outcome was symptomatic recurrence or progression of venous thromboembolism documented by duplex scan examination at regular intervals or earlier if there was any increase in pain, tenderness, or edema of the limbs. Recurrence was defined as the appearance of thrombosis in a previously unaffected venous segment of the ipsilateral or contralateral leg. In asymptomatic patients, recurrent DVT was diagnosed in duplex scan examination follow-up. In patients with clinically suspected pulmonary thromboembolism, the diagnosis was confirmed by the presence of a constant intraluminal filling defect in spiral computed tomography or conventional angiography.
Bleeding during the study was the second outcome event. Bleeding was classified as major if it was overt and was associated with a decrease of 2 g/dL or more in the hemoglobin level, if it required a blood transfusion of 2 units or more, if it was intracranial or retroperitoneal, or if the treatment had to be permanently discontinued. 26, 35, 36 All other episodes of bleeding were defined as minor. Thrombocytopenia was defined as a platelet count below 100,000/µL or a minimum decrease of 40% compared with the baseline value. 35 The final allocation of all potential outcome events, including deaths, was made by an independent panel of physicians. The panel included a member of our team who was not directly involved in the execution of the trial.
Statistical analysis. Analysis was performed with the SPSS 8.0 statistical package (SPSS, Inc, Chicago, Ill) for Windows 95 and Microsoft Excel. A P value less than .05 was considered significant. The tests used were difference of means, the Fisher exact test, and tests for contrast of proportions. Comparisons for nonparametric distributions were performed with the Mann-Whitney U test.
RESULTS

Patients.
From January 1996 to March 1998, 201 consecutive symptomatic patients with confirmed DVT were considered to enter the trial. Of these, 43 were excluded because of age younger than 18 years (1), pregnancy (6), previous ipsilateral DVT (10), history of heparin-induced thrombocytopenia (2), previous treatment with UFH for more than 24 hours (17), lack of staff (2), surgery within the last 5 days (4), and the refusal of informed consent (1) . Therefore, 158 patients were included in the study: 81 (51.3%) were assigned to receive nadroparine, and 77 (48.7%) received acenocoumarol.
There were 69 men and 89 women; ages ranged from 18 to 92 years (mean, 65.7 years). The incidence of various predisposing factors did not vary significantly between the two groups ( Table I ). The average length of stay was 4.0 days (range, 3-5 days) in the LMWH group and 8.5 days (range, 6-15 days) in the OA group.
For 10 patients (6%), two in the LMWH group and eight in the OA group, the medication under study was interrupted before an end point was reached. Nadroparine was withdrawn in a 66-year-old man immobilized in a wheelchair with iliofemoral thrombosis after 30 days of treatment and in an 88-year-old woman with iliofemoral DVT after 2 months of treatment, because of family and another physician's decision. In the OA group, reasons for treatment interruption were rethrombosis (four patients) and major bleeding (four patients). Seventy-eight patients continued treatment for 6 months: 34 in the LMWH group and 44 in the OA group.
Clinical evaluation. During the study period nearly all patients showed improvement in clinical DVT symptoms. At 12-month follow-up, edema was the most frequent sign found; it was found in 38.3% of the LMWH group and in 36.4% of the OA group. No clinical evidence of pathologic fractures or back pain was found during treatment or follow-up.
Laboratory findings. No significant alterations in RBC count and WBC count were found. No thrombocytopenia was observed during treatment or follow-up. The mean platelet count in the two groups showed an increase on the third and seventh days of treatment; it returned to initial values during the surveillance period. In the hematologic unit, control INR values found were less than 2 in 22.8%, 2 to 3 in 67.8%, and more than 3 in 9.4% of the OA group.
Complications. The complications observed in both treatment groups have been summarized in Fig 1 and  Table II .
Recurrent venous thromboembolism.
Nine patients, two (2.5%) of 81 in the LMWH group and seven (9.1%) of 77 in the OA group, had recurrence of DVT; differences were not significant. DVT recurrence involving the limb initially affected was found in two patients (22%), and DVT recurrence in the contralateral limb was found in seven patients (78%) (P = .0023). No isolated recurrences of thrombosis were found in duplex scan examinations without clinical signs.
During different phases of the study, thoracic pain episodes appeared in three patients: a 37-year-old man with mental scores were added to obtain the global scores. The initial mean clot size score was similar in both groups and decreased during follow-up in all DVT locations.
We found that the quantitative duplex scan score showed statistically significant improvement between nadroparine therapy and acenocoumarol therapy after iliofemoral DVT for every checkpoint interval at the first and third months in femoropopliteal DVT and at the first month in infrapopliteal DVT. Mean thrombus size decreased after nadroparine treatment in popliteal DVT and at the 6th and 12th months in femoropopliteal and infrapopliteal thrombosis, but no statistical significance was found with respect to the OA (Fig 2) . OA group at the 6th and 12th months in the CFV and during all follow-up in the SFV and the PV.
Qualitative duplex scan examination showed that at the end of follow-up, the thrombus recanalization rate was higher in the LMWH group versus the OA group in the CFV (63.9% vs 19.3%), the SFV (66.7% vs 14.6%), and the PV (62% vs 27.5%). This difference was found to be statistically significant (P < .000; Table III ).
In 22 (2.8%) of the 786 venous segments evaluated at 3, 6, and 12 months, a worsening of the degree of thrombosis in a previously affected venous segment that was improved in its immediately previous status was found : (Table III) . These events were clinically asymptomatic and were unrelated to specific venous segments, the initial thrombus score, or late development of venous insufficiency. Recanalization after 1 year of follow-up was not affected in these cases in any treatment group.
Venous insufficiency. Reflux patterns at 12 months were similar to those found at the sixth month of followup in superficial, deep, and communicating veins. Table IV shows rates of venous insufficiency at the end of follow-up in limb-thrombosed and contralateral veins.
Incompetence of the long saphenous vein was found more frequently after iliofemoral thrombosis in both groups (P = .0130). The rate of incompetent perforating veins after DVT in the affected limb was higher in the OA group (P = .0289).
DISCUSSION
Drugs.
The DVT was usually treated with a short course of intravenous UFH followed by an OA for at least 3 months. 1 Recently, several trials have shown that initial treatment with various LMWHs was more efficacious and safer than treatment with UFH. 2, 4 To date, the LMWH long-term efficacy has been evaluated in only a few studies, 6, [19] [20] [21] [22] [23] [24] 37 and it has been compared with standard longterm OA treatment in only two of them. 19, 37 In this randomized study we administered nadroparine calcium, an LMWH produced by nitrous acid depolymerization of UFH with a mean molecular weight around 4.5 d. Several studies have demonstrated that nadroparine was as or more effective than the adjusted dose of UFH in the initial treatment of proximal DVT. 35, [38] [39] [40] [41] [42] It was adequate for outpatient treament, 26 it had a lower cost, 43 and probably one daily administration of a more concentrated form of the drug was allowed. 36, 44 The complications after the administration of nadroparine in the initial course of DVT and OAs in longterm treatment have been revealed in previous trials, but the exact comparison of reports is not possible because the drugs used, the dosage schedules, the duration of initial and long-term treatment, time of surveillance periods, and methods of evaluation were different. In the review of medical literature, we found only one case for nadroparine long-term administration after DVT. 22 Our study shows a lower rate of rethrombosis and major bleeding after long-term treatment with nadroparine versus acenocoumarol. However, differences were not significant, perhaps because of the small number of patients (β error). Although the optimal duration of the anticoagulation therapy is still a subject of debate, we administered treatment during 3 months and extended it to 6 months in several patients with proximal, idiopathic DVT or persistent risk factors for thrombosis. We maintained the INR between 2 and 3 when acenocoumarol was administered. 3 Our regimen of long-term nadroparine dosage (twice daily for 3 months and once daily for the following 3 months) is empirical; there are no data regarding the optimal therapeutic range of LMWH dosage during long-term treatment of thromboembolic disease.
In previous studies, researchers reported one daily subcutaneous injection of another LMWH preparation such as dalteparine 37 and enoxiparine 19 for 3 months after the first episode of DVT, but several observations suggest that the failure to achieve an adequate anticoagulant effect early in the course of anticoagulant treatment can lead to later recurrences. 19, 45 We used two daily injections because probably, levels higher than once a day should be preferable at this period.
After this treatment period, we further prolonged the secondary prophylaxis for 3 months in numerous patients; we used nadroparine once a day. The efficacy and safety of this LMWH dosage have been shown during long-term dalteparine administration for up to 70 months. 18 However, the two thrombotic recurrences in the LMWH group occurred 3 months after heparin was stopped, following 6 months of treatment. This may indicate that even this long period of treatment or this dosage was insufficient to prevent new thrombotic events in patients with persistent risk factors for thromboembolic disease.
On the contrary, most recurrences in the OA group occurred during treatment period, with an INR more than 2. This could mean that new thrombotic episodes begin before clinical symptoms appear or routine hematologic laboratory controls are scheduled and could suggest that OA alone is not an eligible treatment in the acute phase of thrombotic disease. 46 Clinical evaluation showed better results than the improvement shown by duplex scan examinations. No thrombus progression was found in duplex scan follow-up in an unaffected venous segment in absence of symptomatic clinical events, 47 although the increases in pain and edema, etc, did not always indicate rethrombosis.
The bleeding appeared in patients with predisposing disorders. 48, 49 The difference in the rate of hemorrhagic complications could mean that the patients' control was better when an LMWH was used.
Nearly all patients who received nadroparine subcutaneously twice a day had small ecchymoses, subcutaneous nodes, or both in the injection site. They were painless and generally well tolerated by patients. These local hematomas improved when nadroparine was administered once a day 19 and disappeared about 15 days after subcutaneous treatment was stopped. Thrombocytopenia was not observed in the followup of this analysis. We found increases in the platelet count on the third and seventh days after initial treatment with nadroparine, as was previously shown with another LMWH. 50 Unfortunately, we have no explanation for this event, and further study of the causal mechanisms is warranted.
In our study, mortality was due to underlying diseases, not to thromboembolic events. 19, 22 There were a similar number of deaths due to advanced malignancy in both groups. Those results do not substantiate the previous hypothesis that LMWH administration may exert a favorable influence on cancer progression, 40,51 even if our regimen of treatment was different.
Overall, the mortality rate was higher than that in other studies, perhaps because we included all patients with cancer in the study, independent of their life expectancy. Except for one patient in the OA group, all other patients were free of thromboembolic complications during the last months of their lives. Although neither treatment prolonged their lives, they did improve their quality of life while they lived.
Post-thrombotic syndrome. Persistent abnormalities may occur after acute DVT, which results in PTS [52] [53] [54] caused by a combination of abnormal microcirculation and venous hypertension resulting from valvular destruction and persistent obstruction to outflow. 55 The hemodynamic severity of chronic obstruction is complex, differing markedly with the level and extent of affected venous segments, 55, 56 the degree of collateralization, and the recanalization that may occur. Some degree of reflux may be present, which also may cause severe symptoms. 57 We used conventional duplex scanning to document the outcome of thrombus itself 9, 56, [58] [59] [60] and the development of valvular incompetence 9, 33, 34, 61 in the deep and superficial venous system during follow-up because the combination of reflux and venous obstruction probably correlates with ulterior PTS development. In previous studies with duplex scan sequential examinations of patients with DVT treated with UFH and OA, it is confirmed that clearance of a thrombus is a gradual process and that recanalization in previously occluded venous segments occurs over various periods. 9, 17, 47, [59] [60] [61] [62] [63] We have not found studies on the long-term evolution of thrombosis after the administration of nadroparine.
The quantitative/qualitative duplex scan score used in this study, which is based in previous histologic, 29 venographic, 32, 64 and duplex thrombosis evaluations, 15, 65 shows a higher proportion of venous recanalization (62%-67%) in proximal venous segments after long-term nadroparine administration. Regression of thrombus size also occurred after OA treatment, although to a lesser degree (15%-27%). The reasons for these results could be associated to some LMWH characteristics (bioavailability > 95% after subcutaneous administration, longer half-life, activity not dose dependent, and low binding to plasma proteins and to proteins released from activated platelets and endothelial cells) 66 that make it possible to maintain more stable levels of anticoagulation, which is not always possible to ensure with an OA, in spite of the performance of frequent laboratory controls. The significant major improvement of thrombi in the LMWH group suggests a thrombolytic effect induced by LMWH, 15, 17, 67 which probably depends on a modulation of the endothelial cell of the vessel wall. 15 During follow-up we found a worsening of the degree of thrombosis in some affected vein segments that had previously improved. This propagation was found incidentally and did not influence the outcome. It may in part reflect only a progressive occupation of the vein lumen, caused by increased thrombus adherence and retraction. 60 However, symptomatic or asymptomatic extension of thrombi into previously unaffected segments represents true propagation of thromboembolic disease.
With color duplex ultrasound scan, it is possible to evaluate the lack of vein competency after DVT. 8, 9, 31, 55, 63, 68 This is a result of either destruction of the valve cusp or incorporation of valves in organizing thrombus. 55, 60 The valve closure time is the test most used to determine the degree of reflux within a specific vein segment. 69 The frequency of reflux in the literature depends heavily on the method used for measuring it and its quantification. There is no consensus about threshold value; this may vary between 0.5 seconds and more than 2 seconds. 34, 53, 69, 70 In a previous study with healthy persons, reflux in the femoral vein induced by a pneumatic cuff showed a value of 0.9 seconds. 71 We have chosen a value of 2 seconds to discriminate valve insufficiency avoiding false-positive results, because the aim of this study is not to establish the frequency of reflux after DVT but to compare the rate of venous insufficiency in two regimens of long-term treatment.
Our findings show a similar frequency of reflux at 6 and 12 months. This confirms the irreversibility of the venous insufficiency that arises at this time after DVT. 61 We found a significantly lower rate of reflux in the communicating veins of patients in the LMWH group, probably because very early recanalization may protect valve function. 1 Furthermore, LMWH has an inhibitory effect on smooth muscle cell proliferation and migra- tion. 16 We have hypothesized that the reduction of local inflammatory response could contribute to the reduction of the fibrotic reaction and thus also residual valvular lesions and the subsequent appearance of reflux. Reflux in deep, superficial, and communicating veins was significantly greater after iliofemoral DVT in both groups. However, the location and extent of reflux were not always associated with thrombosis involvement in the venous segment and are not entirely limited to thrombosed vein segments. 9, 55 The rate of incompetent communicating veins was greater in the OA group. The fact that this proportion is reversed in the involved opposite limb suggests that these findings are associated with the treatment used, rather than with the existence of previous venous insufficiency at that level or systemic factors that cause valvular incompetence. 67 
